Holen Sie sich die Stockscreener-App
31.00
1.71%
-0.54
Handel nachbörslich:
31.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Substance Abuse Treatment Market Set to Witness Digital and Personalized Care Expansion | Indivior, Alkermes - openPR.com
Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com
Nanotechnology Drug Delivery Market Set to Witness Significant - openPR.com
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - The Malaysian Reserve
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | ALKS Stock News - GuruFocus
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - marketscreener.com
Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation? - simplywall.st
Where are the Opportunities in (ALKS) - news.stocktradersdaily.com
Cetera Investment Advisers Increases Stock Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 20 - GuruFocus
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 2025 | ALKS Stock News - GuruFocus
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - PR Newswire
Global Healthcare & Medical Tourism News - Medical Tourism Magazine
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Needham Initiates Coverage on Alkermes (ALKS) with Buy Rating | - GuruFocus
Needham Initiates Alkermes Public at Buy With $45 Price Target - marketscreener.com
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sal - GuruFocus
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sales Projections | ALKS Stock News - GuruFocus
Quantinno Capital Management LP Acquires New Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Controlled Release Drug Delivery Market Generated - openPR.com
Bank of America Corp DE Trims Stake in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes Shareholders Approve Amendments at Annual Meeting - TipRanks
(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alkermes price target raised to $35 from $34 at BofA - MSN
Captrust Financial Advisors Raises Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Nanotechnology Drug Delivery Market Generated Opportunities, - openPR.com
Stifel maintains Alkermes stock Buy rating, $42 target By Investing.com - Investing.com Nigeria
Drug Addiction Treatment Market Projected To Witness Massive - openPR.com
Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com
Cantor Fitzgerald maintains $43 target on Alkermes stock By Investing.com - Investing.com Nigeria
Controlled Release Drug Delivery Market is in trends - openPR.com
Alkermes plc Earnings Call Highlights Growth and R&D Progress - MSN
When the Price of (ALKS) Talks, People Listen - news.stocktradersdaily.com
Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript - Insider Monkey
Alkermes has near-term catalyst with narcolepsy data, says H.C. Wainwright - TipRanks
BlackRock, Inc. Reduces Stake in Alkermes PLC: A Detailed Analysis - GuruFocus
RBC Capital Raises Price Target for Alkermes (ALKS) to $40 | ALKS Stock News - GuruFocus
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates - Nasdaq
Alkermes (ALKS) Reaffirms 2025 Financial Outlook and Awaits Key Trial Results | ALKS Stock News - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | AL - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | ALKS Stock News - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Ou - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Outlook | ALKS Stock News - GuruFocus
RBC Raises Price Target on Alkermes to $40 From $39, Keeps Sector Perform Rating - marketscreener.com
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Pro - GuruFocus
Alkermes: Q1 Earnings Snapshot - MySA
Alkermes plc Reports Q1 2025 Financial Results - TipRanks
1.51%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):